Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.265    -0.005 (-1.85%)
Bid:
0.25
Ask:
0.28
Spread: 0.03 (12.00%)
Market Cap: £15.36m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Pre-close trading update

7 Jul 2022 07:00

RNS Number : 6522R
CAP-XX Limited
07 July 2022
 

 

7 July 2022

CAP-XX Limited

("CAP-XX" or "the Company")

Pre-close trading update

 

CAP-XX Limited, a world leader in the design and manufacture of thin, prismatic supercapacitors and energy management systems, announces a trading update in respect of the financial year ended 30 June 2022.

The Company is pleased to announce that revenues and adjusted EBITDA* for the year ended 30 June 2022 are, subject to clearance by CAP-XX's independent auditors, expected to be in line with current market expectations. Product sales are up 39% by value on the previous year and total revenue up 31% on the previous year at A$5.6m. Adjusted EBITDA* is expected to be a loss of (A$699K), after excluding A$2.4m in legal fees associated with the AVX and Maxwell court cases. EBITDA for FY22 is expected to be a loss of (A$3.1m) when the A$2.4m in legal fees are included.

Both court cases are progressing favourably and the Board, under advice from our lawyers, remains confident of the Company's prospects of securing a favourable outcome. This has enabled the Board to secure litigation funding which is expected to be in place to cover the legal fees in FY23. Legal fees associated with these cases in FY22 were approximately A$2.0m higher than previously forecast as the cases moved closer to resolution and legal fees were incurred sooner than expected.

The Board is encouraged by the outlook for FY23 and beyond and expects to see continued strong growth in product sales. This growth is being driven by increasing customer demand for DMF and DMT products, cylindrical supercapacitors and traditional supercapacitor products made in Malaysia. In addition new products, such as LICs together with the expansion of our distribution channels are expected to increase sales. Commissioning of the DMH line is expected to be completed around the middle of 2023, as time and resources allow, and subject to customer demand.

Cash reserves as at the end of June 2022 were approximately A$1.6m

The Company's results for the year ended 30 June 2022 are expected to be released on 29 September 2022.

* Adjusted EBITDA excludes the Company's legal expenses associated with its patent infringement actions.

 

 

For further information contact:

CAP-XX Limited

Anthony Kongats (CEO)

 

+61 (0) 2 9428 0139

Kreab (Financial PR)

Robert Speed

 

+44 (0) 20 7074 1800

Allenby Capital (Nominated Adviser and Joint Broker)

David Hart / Alex Brearley (Corporate Finance)

Tony Quirke (Sales and Corporate Broking)

 

+44 (0) 20 3328 5656

Cenkos Securities plc (Joint Broker)

Neil McDonald / Pete Lynch

 

+44 (0) 13 1220 6939

 

More information is available at www.cap-xx.com

 

Notes to Editors:

 

CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and to an increasing extent, in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUBPMUPPUCM
Date   Source Headline
2nd Jul 20197:00 amRNSUS court action settlement and licence agreement
25th Jun 201910:45 amRNSIssue of Shares and Director/PDMR Shareholdings
7th Jun 20198:59 amRNSHolding(s) in Company
6th Jun 20199:03 amRNSTrading Update
30th May 20198:27 amRNSHolding(s) in Company
17th Apr 20193:09 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSTrading Update
6th Mar 20197:00 amRNSInterim Results
1st Mar 20197:36 amRNSDirector Disclosure Update
22nd Jan 20198:32 amRNSHolding(s) in Company
20th Dec 20188:43 amRNSIssue of Shares and Director/PDMR Shareholdings
20th Nov 20188:29 amRNSResult of AGM and Chairman's AGM statement
14th Nov 20187:00 amRNSHolding(s) in Company
5th Nov 20187:00 amRNSSubscription to raise £1.75 million
23rd Oct 20187:00 amRNSExercise of share options & PDMR shareholding
22nd Oct 201810:09 amRNSNotice of AGM
17th Oct 20187:00 amRNSAudited results for the year ended 30 June 2018
8th Oct 20182:05 pmRNSSecond Price Monitoring Extn
8th Oct 20182:00 pmRNSPrice Monitoring Extension
8th Oct 20187:00 amRNSNew licence agreement with TDK
5th Oct 20188:00 amRNSNotice of Results
25th Sep 201810:22 amRNSSpire Health Tags launched in Apple stores
18th Jul 20188:30 amRNSDirector/PDMR Shareholding
13th Jul 20187:00 amRNSExercise of share options
22nd Jun 20187:00 amRNSIssue of Shares and Director/PDMR Shareholdings
21st Jun 20187:00 amRNSExercise of share options & PDMR shareholding
20th Jun 20187:00 amRNSTrading update
1st May 20187:00 amRNSExercise of employee share options
11th Apr 20187:00 amRNSDeveloping first 3V thin prismatic supercapacitors
6th Mar 20182:25 pmRNSInterim Results (Replacement)
6th Mar 20187:00 amRNSInterim Results
15th Feb 20188:46 amRNSNotice of results
16th Jan 20187:00 amRNSHolding(s) in Company
18th Dec 201711:42 amRNSGrant of Share Options
12th Dec 201710:35 amRNSIssue of Shares and Director/PDMR Shareholdings
23rd Nov 20179:40 amRNSResult of AGM and Chairman's AGM statement
20th Nov 20177:00 amRNSSpire launches Thinline enabled wearable
30th Oct 20177:00 amRNSNotice of AGM
9th Oct 20177:00 amRNSAudited results for the year ended 30 June 2017
22nd Sep 20178:59 amRNSHolding(s) in Company
22nd Sep 20177:00 amRNSNotice of Results
23rd Aug 20178:37 amRNSHolding(s) in Company
15th Aug 20177:00 amRNSFirst high-volume order for Thinline
29th Jun 20178:22 amRNSIssue of Shares and Director/PDMR Shareholdings
7th Jun 20177:00 amRNSTrading update for year ending 30 June 2017
25th May 20178:51 amRNSExtension of option term and Director/PDMR dealing
19th Apr 20178:47 amRNSHolding(s) in Company
20th Mar 20177:00 amRNSInterim Results
9th Mar 20177:00 amRNSCAP-XX launches new cylindrical supercapacitors
1st Feb 20177:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.